WuXi STA To Purchase BMS Mfg Facility in SwitzerlandBy
WuXi STA, a subsidiary of WuXi AppTec, has agreed to purchase Bristol-Myers Squibb’s manufacturing facility in Couvet, Switzerland. The facility has commercial-scale production capacity for capsule and tablet dosage forms.
The companies anticipate completing the transaction by the second quarter of 2021, subject to regulatory approvals and the satisfaction of other closing conditions. Upon closing, WuXi STA will acquire the Couvet site’s operations and assets, which include the plant and equipment, as well as a workforce with technical capabilities and expertise.
The Couvet site will be the first facility in Europe for WuXi STA. The Couvet facility will continue to operate as part of Bristol-Myers Squibb’s manufacturing network until the closing of the transaction.